| Popis: |
In 1933, the observation was made that an extract of hemolytic streptococci lyses fibrin (Tillett and Garner 1933), and it took 16 years for a therapeutic preparation, streptococcal fibrinolysin (streptokinase), to be used clinically to dissolve fibrinous pleural effusions (Tillett and Sherry 1949). By the 1950s, investigators thrombi and in acute myocardial infarction (AMI) (Johnson and Tillett 1952; Fletcher et al. 1959a,b), and in the late 1960s and 1970s it was widely applied in Europe for the treatment of deep venous thrombosis and pulmonary embolism (reviewed by Francis and Marder 1991). SK is derived from a non-pathogenic, group C (Lancefield) strain of streptococci (see Chap.2), and was the first thrombolytic agent developed for clinical usage, providing the basis for comparison with other thrombolytic agents. |
